Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-25-001232
Filing Date
2025-01-03
Accepted
2025-01-03 16:30:05
Documents
2
Period of Report
2025-01-01

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5910
2 EX-24.POA ntla-ex24_poa.htm EX-24.POA 9988
  Complete submission text file 0000950170-25-001232.txt   17381
Mailing Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139
Business Address 40 ERIE STREET SUITE 130 CAMBRIDGE MA 02139 857-285-6200
Intellia Therapeutics, Inc. (Issuer) CIK: 0001652130 (see all company filings)

EIN.: 364785571 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Business Address
Sepp-Lorenzino Laura (Reporting) CIK: 0001777421 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-37766 | Film No.: 25506773